| Drug Name | Xofigo (Radium-223 dichloride) |
|---|---|
| Drug Class | |
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Updates to strength expression, dose regimens in DVT/PE, use in patients with severe renal impairment .fracture and trend for increased mortality. |
| Dear Healthcare provider letter DHPC |
|